CRIS Current Research Information System

SARTOR, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.268
EU - Europa 2.635
AS - Asia 1.724
AF - Africa 220
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 6
SA - Sud America 6
Totale 7.866
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.256
GB - Regno Unito 703
IT - Italia 594
VN - Vietnam 568
CN - Cina 445
SE - Svezia 445
SG - Singapore 442
DE - Germania 322
IN - India 145
IE - Irlanda 126
TG - Togo 82
FR - Francia 81
RU - Federazione Russa 73
ZA - Sudafrica 56
EE - Estonia 54
NG - Nigeria 47
BG - Bulgaria 43
JO - Giordania 38
CH - Svizzera 33
UA - Ucraina 33
FI - Finlandia 31
CI - Costa d'Avorio 30
BE - Belgio 20
ID - Indonesia 16
IR - Iran 16
NL - Olanda 14
JP - Giappone 12
CA - Canada 11
GR - Grecia 10
PL - Polonia 9
ES - Italia 7
HK - Hong Kong 7
UZ - Uzbekistan 7
EU - Europa 6
AT - Austria 5
AU - Australia 5
LT - Lituania 5
TR - Turchia 5
HR - Croazia 4
LB - Libano 4
MK - Macedonia 4
RS - Serbia 4
BD - Bangladesh 3
CL - Cile 3
CZ - Repubblica Ceca 3
KR - Corea 3
BY - Bielorussia 2
HU - Ungheria 2
MA - Marocco 2
PE - Perù 2
PK - Pakistan 2
PT - Portogallo 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BR - Brasile 1
EG - Egitto 1
GE - Georgia 1
IL - Israele 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LI - Liechtenstein 1
LU - Lussemburgo 1
LV - Lettonia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PA - Panama 1
SA - Arabia Saudita 1
SC - Seychelles 1
TM - Turkmenistan 1
TW - Taiwan 1
UG - Uganda 1
Totale 7.866
Salva come PNG Salva come JPEG
Città #
Southend 663
Chandler 429
Dong Ket 418
Singapore 392
Fairfield 271
Ashburn 230
Ann Arbor 180
Houston 158
Wilmington 145
Woodbridge 145
Princeton 134
Dublin 126
Seattle 119
Boardman 115
Bologna 115
Santa Clara 102
Cambridge 98
Beijing 89
Lomé 82
New York 56
Westminster 55
Padova 52
Nanjing 50
Abeokuta 47
Milan 46
Medford 44
Sofia 43
Amman 38
Berlin 37
Bremen 36
Abidjan 30
Helsinki 29
Redmond 29
Saint Petersburg 27
Bern 26
Redwood City 26
San Diego 25
Turin 25
Florence 24
Brussels 20
Hebei 20
Jinan 20
Rome 20
Shenyang 20
Changsha 17
Jiaxing 17
Nanchang 17
Jakarta 16
Tianjin 14
Mountain View 12
Falls Church 11
Los Angeles 11
Zhengzhou 11
Guangzhou 10
Norwalk 10
Forlì 8
Dehradun 7
Des Moines 7
Fuzhou 7
Haikou 7
Shanghai 7
Toronto 7
Boydton 6
Dearborn 6
Hyderabad 6
Leawood 6
Paris 6
Reggio Emilia 6
Taizhou 6
Tokyo 6
Wuhan 6
Andover 5
Augusta 5
Faenza 5
Hangzhou 5
Henderson 5
Hong Kong 5
Irvine 5
Kraków 5
London 5
Madrid 5
Monmouth Junction 5
Olalla 5
Vienna 5
Athens 4
Bitola 4
Busseto 4
Casalecchio di Reno 4
Cesena 4
Chengdu 4
Frankfurt am Main 4
Fremont 4
Groningen 4
Ningbo 4
Osimo 4
Sacramento 4
Svilajnac 4
Taiyuan 4
Tappahannock 4
Wenzhou 4
Totale 5.235
Salva come PNG Salva come JPEG
Nome #
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 230
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 195
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 188
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 188
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 187
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 179
A case report of acute myeloid leukemia and neurofibromatosis 1 174
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 174
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 155
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 147
Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients 146
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 144
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 143
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 142
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 131
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 130
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 127
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia 127
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 125
CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL): THE BOLOGNA EXPERIENCE 124
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 123
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 122
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 122
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 121
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 120
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 119
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 119
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 117
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 116
COMPLEX GENETIC HETEROGENEITY INFLUENCES PROGNOSIS IN ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA NEGATIVE FOR RECURRENT FUSION GENES 115
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 109
SNP array reveals a new deletion of JAK2 in AML patients 107
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 106
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 105
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 104
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 103
Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing SMAD4 mutation with acute lymphoblastic leukemia Philadelphia positive and juvenile polyposis hereditary hemorrhagic telangiectasia syndrome 100
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 99
HIGH RATE OF COMPLETE HEMATOLOGICAL RESPONSE IN ELDERLY PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS BY INNOVATIVE SEQUENTIAL USE OF NILOTINIB AND IMATINIB: A GIMEMA CLINICAL TRIAL LAL 1408 97
PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience 97
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: the Bologna experience 97
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 95
A Three-Genes Signature of Anti-Apoptotic Genes Showed Different Mechanisms in Preventing Apoptosis in Acute Myeloid Leukemia Cells and Could Provide an Useful Model to Establish the Proper BH3-Mimetich Drug or Combination 92
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 91
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 91
Early low-dose computed tomography with pulmonary angiography to improve the early diagnosis of invasive mould disease in patients with haematological malignancies: A pilot study 91
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 90
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 87
Sequential use of first and second generation TKIs are effective on prolonged overall survival in elderly population affected by Ph+ acute lymphoblastic leukemia: the GIMEMA experience 85
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 85
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 85
Nelarabine front-line therapy for adult T-Lymphoblastic leukaemia/Lymphoma (T-LBL/ALL): preliminary results of a single centre experience 84
New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients 82
Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells 79
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 78
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia 78
Nelarabine front-line therapy for adult T-lymphoblastic leukemia/lymphoma (T-LBL/ALL): preliminary results of a single center experience. 75
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: follow up of a single-center Italian compassionate use 74
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant 73
Synergism through WEE1 and CHK1 inhibition in acute lymphoblastic leukemia 71
[Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering"] 70
NELARABINE FRONT-LINE THERAPY FOR ADULT T-LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA (T-LBL/ALL): PRELIMINARY RESULTS OF BOLOGNA EXPERIENCE 69
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients 62
INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia 60
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 59
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 55
null 52
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 51
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment 50
null 50
Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement 49
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia 44
A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure 43
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia 32
MPN-182 Droplet Digital PCR for Non-Invasive Detection of the KIT D816V Mutation in the Peripheral Blood of Patients With Suspected Systemic Mastocytosis 32
Posterior reversible encephalopathy syndrome in a B-cell acute lymphoblastic leukemia young adult patient treated with a pediatric-like chemotherapeutic schedule 32
Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis 32
Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment 31
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 27
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 26
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 25
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax 19
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease 19
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study 15
Acute myeloid leukemia mutations: Therapeutic implications 14
Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin 13
Management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP): Results from a survey among allergists and clinical immunologists of the North-west and Center Italy Inter-Regional Sections of SIAAIC and otorhinolaryngologists of National IAR 12
Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission 6
Rationale for a Pediatric-Inspired Approach in the Adolescent and Young Adult Population with Acute Lymphoblastic Leukemia, with a Focus on Asparaginase Treatment 6
Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax / hypomethylating agents 6
Posterior Reversible Encephalopathy Syndrome in a B-Cell Acute Lymphoblastic Leukemia Young Adult Patient Treated with a Pediatric-like Chemotherapeutic Schedule 3
Totale 8.124
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.096
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.096
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.005 0 0 0 0 127 99 157 180 184 114 96 48
2020/20211.144 138 40 19 19 23 41 27 60 103 30 66 578
2021/20221.506 140 35 69 141 137 65 33 117 69 125 322 253
2022/20231.841 184 254 74 235 197 154 49 115 310 45 137 87
2023/2024602 16 73 38 62 38 118 43 62 31 39 53 29
2024/20251.082 113 361 212 207 189 0 0 0 0 0 0 0
Totale 8.124